Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Industry

13 Jul 2022

PharmaTher Granted Patent For Ketamine and Parkinson’s

Today we received another addition to PharmaTher's IP stockpile with a new patent for ketamine and the treatment of Parkinson’s and other motor disorders....

By Jason Najum

Finance

8 Jul 2022

Psychedelic Stocks: Have We Finally Hit Bottom?

Psychedelic stock prices....

By Jason Najum

Culture, Industry

6 Jul 2022

A Look at Psychedelics in the Media

Let’s take a look at recent psychedelic medicine headlines and see what the media has been saying as of late....

By Jason Najum

Industry

6 Jul 2022

ATAI Files For Potential $300M Capital Raise

Atai has filed a shelf prospectus for up tp $300 million in new capital...

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

27 Jun 2022

Compass Wins Patent Case; MindMed Granted Patent For MDMA and LSD

Compass Pathways and MindMed get patent wins in controversial patent claims...

By Jason Najum

Industry, Science

22 Jun 2022

New DMT Study Shows Positive Results for Depression

A new study published in Nature has a variety of interesting results for the use of DMT, showing positive results for depression and potential for easier patient access....

By Jason Najum

Industry

17 Jun 2022

Top Clinical Trials in 2022 (Part 2)

The success or failure of the sector’s advanced clinical trials will dictate the future of the industry....

By Jason Najum

Finance

15 Jun 2022

Small Pharma Gets Big Price Target From Two Analysts

Following this trend of confidence in mid-tier companies with good capital reserves, we have a string of positive coverage for Small Pharma....

By Jason Najum

Finance

14 Jun 2022

Canaccord Gives Cybin 10x Price Target

We have another major analyst, Canaccord Genuity, coming out with strong buy ratings for Cybin....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.